A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression
Nemets B, Levine J
International clinical psychopharmacology · 26 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- National Alliance for Research on Schizophrenia and Depression
- Gobierno
- National Institute of Neurological Disorders and Stroke
Según 2 financiadores declarados.
Publicación
- Publicado
- 2013-03-06 · Int Clin Psychopharmacol · vol. 28 · número 3 · págs. 127–133
- Editorial
- Wolters Kluwer
- Citado
- 31 citas · más que el 80% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Treatment of Major Depression · Tryptophan and brain disorders · Electroconvulsive Therapy Studies
- Palabras clave
- creatine monohydrate, antidepressant augmentation, major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, brain energy metabolism, dose-finding, treatment-resistant depression, women
- MeSH
- humans, creatine, antidepressive agents, treatment outcome, drug therapy, combination, pilot projects, double-blind method, psychiatric status rating scales, dose-response relationship, drug, drug synergism, adult, aged, middle aged, female, male, selective serotonin reuptake inhibitors, major depressive disorder
2 autores
- Boris Nemets🇮🇱Ben-Gurion University of the Negev
- Joseph Levine🇮🇱 · autor de correspondenciaBen-Gurion University of the Negev
Resumen
El texto original del estudio, en el idioma en que se publicó.
Creatine's effects on brain energy metabolism raise the possibility of developing a new therapeutic strategy in depression focusing on the treatment of metabolic hypoactive brain areas. Previous creatine augmentation studies in patients with major depression showed a beneficial effect. Eighteen patients (14 women) with major depression not responding to previous 3 weeks of antidepressant treatment were enrolled into a pilot, dose finding, 4-week double-blind parallel augmentation study where creatine monohydrate 5 or 10 g daily or placebo was added to ongoing SSRIs/SNRIs/NASA treatment. Rating scales included the Hamilton Depression Rating Scale and the Clinical Global Impression Severity scale. Overall, there was no difference between creatine administered at 5 or 10 g daily and its corresponding placebos. Two female patients on creatine augmentation, but none on the placebo, showed early improvement of more than 50% reduction in Hamilton Depression Rating Scale after 2 weeks of creatine treatment. No clinically relevant side effects were reported. This preliminary study seems to suggest that the strategy using creatine augmentation in major depressive women showing no 'real-life response' to 3 weeks of treatment with SSRIs/SNRIs/NASA treatment is of no advantage compared with placebo. However, such creatine augmentation may still induce a more rapid response in a small subgroup of these female patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.